Study identifier:CD-ID-MEDI4893-1133
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin, in Healthy Adult Subjects
Staphylococcus aureus
Phase 1
Yes
Placebo, MEDI4893
All
85
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Other
Verified 01 Jul 2014 by MedImmune, LLC
MedImmune, LLC
-
No locations available
Arms | Assigned Interventions |
---|---|
Placebo Comparator: Placebo | Drug: Placebo Placebo Other Name: Placebo |
Active Comparator: MEDI4893 | Drug: MEDI4893 Human immunoglobulin G1 kappa monoclonal antibody Other Name: Active comparator |